Amgen AMGN announced that it made an additional investment of approximately $421 million in its China-based collaborator for oncology products, BeiGene BGNE.Amgen made the investment through purchase of BeiGene's registered direct offering of ordinary shares to certain existing investors, announced by the company earlier this week.